162 related articles for article (PubMed ID: 36805789)
21. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
22. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
23. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
24. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
[TBL] [Abstract][Full Text] [Related]
25. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract][Full Text] [Related]
26. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.
Otsuka I
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922503
[TBL] [Abstract][Full Text] [Related]
28. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
29. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
30. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
32. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
33. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract][Full Text] [Related]
34. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
35. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
36. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
[TBL] [Abstract][Full Text] [Related]
37. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
38. Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis.
Zhang T; Zhou X; Zhang X; Niu S; Chen H; Zhou F
Virchows Arch; 2023 Apr; 482(4):755-766. PubMed ID: 36806916
[TBL] [Abstract][Full Text] [Related]
39. Spectrum of
Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
[TBL] [Abstract][Full Text] [Related]
40. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
